4,053 Shares in DexCom, Inc. (NASDAQ:DXCM) Bought by Legacy Wealth Asset Management LLC

Legacy Wealth Asset Management LLC bought a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 4,053 shares of the medical device company's stock, valued at approximately $315,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Versant Capital Management Inc bought a new stake in DexCom in the 4th quarter valued at about $25,000. Riverview Trust Co increased its stake in shares of DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock worth $31,000 after purchasing an additional 232 shares in the last quarter. RPg Family Wealth Advisory LLC bought a new stake in shares of DexCom in the third quarter valued at approximately $57,000. Covestor Ltd lifted its stake in shares of DexCom by 53.7% during the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company's stock valued at $64,000 after buying an additional 335 shares in the last quarter. Finally, Blue Trust Inc. boosted its holdings in DexCom by 101.9% in the 3rd quarter. Blue Trust Inc. now owns 1,779 shares of the medical device company's stock worth $119,000 after buying an additional 898 shares during the period. 97.75% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

DXCM has been the topic of several recent research reports. Sanford C. Bernstein increased their target price on DexCom from $82.00 to $86.00 and gave the stock an "outperform" rating in a research report on Friday, October 25th. Leerink Partners cut their target price on DexCom from $90.00 to $87.00 and set an "outperform" rating for the company in a research note on Friday, October 25th. Baird R W upgraded DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday. Raymond James cut their price objective on shares of DexCom from $115.00 to $99.00 and set a "strong-buy" rating for the company in a research report on Friday, October 25th. Finally, JPMorgan Chase & Co. upped their target price on shares of DexCom from $75.00 to $85.00 and gave the stock a "neutral" rating in a report on Friday, October 25th. Five equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $99.29.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.30% of the company's stock.

DexCom Stock Performance

NASDAQ:DXCM opened at $84.38 on Friday. The company has a market capitalization of $32.96 billion, a price-to-earnings ratio of 50.53, a PEG ratio of 2.00 and a beta of 1.12. The business has a 50 day moving average of $78.17 and a 200 day moving average of $78.22. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.